Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
Robert J Commons*, Megha Rajasekhar*, Peta Edler, Tesfay Abreha, Ghulam R Awab, J Kevin Baird, Bridget E Barber, Cindy S Chu, Liwang Cui, André Daher, Lilia Gonzalez-Ceron, Matthew J Grigg, Jimee Hwang, Harin Karunajeewa, Marcus V G Lacerda, Simone Ladeia-Andrade, Kartini Lidia, Alejandro Llanos-Cuentas, Rhea J Longley, Dhelio B Pereira, Ayodhia P Pasaribu, Sasithon Pukrittayakamee, Komal R Rijal, Inge Sutanto, Walter R J Taylor, Pham V Thanh, Kamala Thriemer, José Luiz F Vieira, James A Watson, Lina M Zuluaga-Idarraga, Nicholas J White, Philippe J Guerin, Julie A Simpson, Ric N Price, on behalf of the WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group†
This study undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P.vivax recurrence.